Bristol Myers Squibb Co (BMY) Asset Writedowns and Impairment (2010 - 2026)

Bristol Myers Squibb (BMY) has reported Asset Writedowns and Impairment for 17 consecutive years, with $422.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Asset Writedowns and Impairment rose 34.82% year-over-year to $422.0 million; the TTM figure through Jun 2026 stood at $1.6 billion (down 33.03% YoY), while the FY2025 annual figure was $1.1 billion, down 62.94% from the prior year.
• Asset Writedowns and Impairment climbed to $422.0 million in Q2 2026 per BMY's latest filing, from $412.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $2.0 billion in Q4 2024 and bottomed at $1.0 million in Q1 2024.
• Historically, Asset Writedowns and Impairment has averaged $296.1 million across 5 years, with a median of $100.0 million in 2022.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment sank 95.0% — and 2026, when it soared 8140.0%.
• Bristol Myers Squibb's Asset Writedowns and Impairment stood at $35.0 million in 2022, then dropped by 17.14% to $29.0 million in 2023, then jumped by 6634.48% to $2.0 billion in 2024, then tumbled by 70.1% to $584.0 million in 2025, then dropped by 27.74% to $422.0 million in 2026.
• Business Quant data shows BMY's Asset Writedowns and Impairment at $422.0 million in Q2 2026, $412.0 million in Q1 2026, and $584.0 million in Q4 2025.